Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Scheffler

Showing results (181-190 of 207) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Oncotarget|December 5, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignanciesMatthias Scheffler, Marc Bos, Masyar Gardizi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Nucleic Acids Research|November 25, 2003
Validation of a novel, fully integrated and flexible microarray benchtop facility for gene expression profilingMichael Baum, Simone Bielau, Nicole Rittner, et al.
Cancer Medicine|May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessmentLucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Cancer Discovery|December 5, 2013
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerFlorian Malchers, Felix Dietlein, Jakob Schöttle, et al.
Scientific Data|September 14, 2023
Shared metadata for data-centric materials scienceLuca M Ghiringhelli, Carsten Baldauf, Tristan Bereau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2015
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer PatientsKatharina König, Martin Peifer, Jana Fassunke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
Pageof 21

Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Oncotarget|December 5, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignanciesMatthias Scheffler, Marc Bos, Masyar Gardizi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Nucleic Acids Research|November 25, 2003
Validation of a novel, fully integrated and flexible microarray benchtop facility for gene expression profilingMichael Baum, Simone Bielau, Nicole Rittner, et al.
Cancer Medicine|May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessmentLucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Cancer Discovery|December 5, 2013
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerFlorian Malchers, Felix Dietlein, Jakob Schöttle, et al.
Scientific Data|September 14, 2023
Shared metadata for data-centric materials scienceLuca M Ghiringhelli, Carsten Baldauf, Tristan Bereau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2015
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer PatientsKatharina König, Martin Peifer, Jana Fassunke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
Pageof 21